The lawsuit involving the chemotherapy drug Taxotere states the manufacturer of Taxotere (Sanofi-Aventis) failed to warn patients and physicians of the increased risks of permanent alopecia (loss of hair).
Claims are being filed against Sanofi-Aventis by women who have suffered permanent hair loss as a result of being prescribed Taxotere.To get details about Monsanto Taxotere Hair Loss Lawsuits, you can click right over it.
Attorneys state that if the manufacturer had properly warned of the risks, patients would have been prescribed a different chemotherapy drug called Taxol, which is more effective than Taxotere, and does not result in permanent hair loss.
Taxotere (docetaxel) is a chemotherapy drug approved for the treatment of breast cancer, non-small cell lung cancer, advanced stomach cancer, head and neck cancer and metastatic prostate cancer. It is administered intravenously through a vein and is the member of a family of drugs called taxanes. It is used to try to prevent cancer cells from growing and dividing
Taxotere is normally used in combination with other drugs such as capecitabine, cisplatin, fluorouracil, doxorubicin, and cyclophosphamide to fight off cancer and provide patients with better survival rates.
It acts as an anti-mitotic agent, meaning that it disrupts cellular division. It is usually administered intravenously during one hour-long infusion cycles that are then repeated every 3-4 weeks.